Rifampin Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
See Also
How Supplied
Manufacturer
Mechanism of Action
Rifampin Indications
Indications
Rifampin Dosage and Administration
Adult
Children
Rifampin Contraindications
Contraindications
Concomitant ritonavir-boosted saquinavir (increased risk of severe hepatotoxicity). Concomitant atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir. Concomitant praziquantel. Concomitant lurasidone. Rifamycin hypersensitivity.
Rifampin Boxed Warnings
Not Applicable
Rifampin Warnings/Precautions
Warnings/Precautions
Meningococcal: reserve rifampin for cases where high risk of meningococcal disease exists; confirm diagnosis. Not recommended for intermittent therapy (risk of rare renal hypersensitivity reactions). Monitor for hypersensitivity or severe cutaneous reactions (eg, SJS, TEN, DRESS); discontinue if occur. Monitor for signs of liver injury (esp. in prolonged treatment). If hepatic impaired: obtain LFTs at baseline, then every 2–4 weeks during therapy. Discontinue if signs of hepatic damage occur or worsen. Vitamin K-dependent coagulation disorders, bleeding; monitor. Pulmonary toxicity. Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura, hemolytic uremia syndrome). Diabetes. May stain teeth, body secretions, contact lenses. IV: avoid extravasation. Elderly. Pregnancy. Nursing mothers: not recommended.
Rifampin Pharmacokinetics
Absorption
Readily absorbed from the gastrointestinal tract. Absorption is reduced by about 30% when taken with food.
Distribution
Widely distributed throughout the body. Plasma protein bound: ~80%.
Elimination
Renal (up to 30%). Half-life: ~3.35±0.66 hours (after a 600 mg oral dose); 5.08±2.45 hours (after a 900 mg dose).
Rifampin Interactions
Interactions
Rifampin Adverse Reactions
Adverse Reactions
GI disturbances, jaundice, headache, fever, drowsiness, fatigue, ataxia, dizziness, inability to concentrate, mental confusion, muscular weakness, pain in extremities, generalized numbness, visual disturbances, elevated BUN and serum uric acid, menstrual disturbances, urticaria, rash, edema; hepatotoxicity, hepatitis, abnormal LFTs, cholestasis, paradoxical drug reaction, interstitial lung disease; rare: blood dyscrasias, anaphylaxis.
Rifampin Clinical Trials
See Literature
Rifampin Note
Notes
Rifampin Patient Counseling
See Literature
Rifampin Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
See Also
How Supplied
Manufacturer
Mechanism of Action
Rifampin Indications
Indications
Rifampin Dosage and Administration
Adult
Children
Rifampin Contraindications
Contraindications
Concomitant ritonavir-boosted saquinavir (increased risk of severe hepatotoxicity). Concomitant atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir. Concomitant praziquantel. Concomitant lurasidone. Rifamycin hypersensitivity.
Rifampin Boxed Warnings
Not Applicable
Rifampin Warnings/Precautions
Warnings/Precautions
Meningococcal: reserve rifampin for cases where high risk of meningococcal disease exists; confirm diagnosis. Not recommended for intermittent therapy (risk of rare renal hypersensitivity reactions). Monitor for hypersensitivity or severe cutaneous reactions (eg, SJS, TEN, DRESS); discontinue if occur. Monitor for signs of liver injury (esp. in prolonged treatment). If hepatic impaired: obtain LFTs at baseline, then every 2–4 weeks during therapy. Discontinue if signs of hepatic damage occur or worsen. Vitamin K-dependent coagulation disorders, bleeding; monitor. Pulmonary toxicity. Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura, hemolytic uremia syndrome). Diabetes. May stain teeth, body secretions, contact lenses. IV: avoid extravasation. Elderly. Pregnancy. Nursing mothers: not recommended.
Rifampin Pharmacokinetics
Absorption
Readily absorbed from the gastrointestinal tract. Absorption is reduced by about 30% when taken with food.
Distribution
Widely distributed throughout the body. Plasma protein bound: ~80%.
Elimination
Renal (up to 30%). Half-life: ~3.35±0.66 hours (after a 600 mg oral dose); 5.08±2.45 hours (after a 900 mg dose).
Rifampin Interactions
Interactions
Rifampin Adverse Reactions
Adverse Reactions
GI disturbances, jaundice, headache, fever, drowsiness, fatigue, ataxia, dizziness, inability to concentrate, mental confusion, muscular weakness, pain in extremities, generalized numbness, visual disturbances, elevated BUN and serum uric acid, menstrual disturbances, urticaria, rash, edema; hepatotoxicity, hepatitis, abnormal LFTs, cholestasis, paradoxical drug reaction, interstitial lung disease; rare: blood dyscrasias, anaphylaxis.
Rifampin Clinical Trials
See Literature
Rifampin Note
Notes
Rifampin Patient Counseling
See Literature